SEStephen E. Epstein

Stephen E. Epstein

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stephen E. Epstein has a total of 81 co-authors. Here are the top co-authors by number of shared publications:

  • Mary Susan Burnett

    From the Cardiovascular Research Institute, MedStar Health Research Institute, Washington, DC (S.E.E., R.M.L.-S., M.S.B.), and Department of Physiology and McAllister Heart Institute, University of North Carolina, Chapel Hill, NC (J.E.F.).

    5 shared publications
  • Eugenio Stabile

    Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy

    4 shared publications
  • Mary Susan Burnett

    Cardiovascular Research Institute, MedStar Health Research Institute, 108 Irving Street, NW Washington, DC 20010, USA

    4 shared publications
  • Ron Waksman

    From the MedStar Washington Hospital Center, Washington, DC (D.L., M.J.L., P.C.W., R.W., S.E.E.); University of Virginia, Charlottesville (D.K.G., J.D.); Universidad CEU Cardenal Herrera, Valencia, Spain (J.C.F.); GIBI230, Grupo de Investigación Biomédica en Imagen, IIS La Fe, Valencia, Spain (M.T.A.); and CardioCell Inc, San Diego, CA (S.S., A.K., G.V.).

    4 shared publications
  • Amir H. Najafi

    Cardiovascular Research Institute, MedStar Health Research Institute, Washington Hospital Center

    3 shared publications
  • Kenneth M. Kent

    3 shared publications

Latest Publications

  • Intravenously Delivered Mesenchymal Stem Cells

    by Dror Luger, Michael J. Lipinski, Peter C. Westman, David K. Glover, Julien Dimastromatteo, Juan C. Frias, M. Teresa Albelda, Sergey Sikora, Alex Kharazi, Grigory Vertelov, et al.

    Rationale:: Virtually all mesenchymal stem cell (MSC) studies assume that therapeutic effects accrue from local myocardial effects of engrafted MSCs. Because few intravenously administered MSCs engraft in the myocardium, studies have mainly utilized direct myocardial delivery. We adopted a different paradigm. Objective:: To test whether intravenously administered MSCs reduce left ventricular (LV) dysfunction both post–acute myocardial infarction and in ischemic cardiomyopathy and that these effects are caused, at least partly, by systemic anti-inflammatory activities. Methods and Results:: Mice underwent 45 minutes of left anterior descending artery occlusion. Human MSCs, grown chronically at 5% O 2 , were administered intravenously. LV function was assessed by serial echocardiography, 2,3,5-triphenyltetrazolium chloride staining determined infarct size, and fluorescence-activated cell sorting assessed cell composition. Fluorescent and radiolabeled MSCs (1×10 6 ) were injected 24 hours post–myocardial infarction and homed to regions of myocardial injury; however, the myocardium contained only a small proportion of total MSCs. Mice received 2×10 6 MSCs or saline intravenously 24 hours post–myocardial infarction (n=16 per group). At day 21, we harvested blood and spleens for fluorescence-activated cell sorting and hearts for 2,3,5-triphenyltetrazolium chloride staining. Adverse LV remodeling and deteriorating LV ejection fraction occurred in control mice with large infarcts (≥25% LV). Intravenous MSCs eliminated the progressive deterioration in LV end-diastolic volume and LV end-systolic volume. MSCs significantly decreased natural killer cells in the heart and spleen and neutrophils in the heart. Specific natural killer cell depletion 24 hours pre–acute myocardial infarction significantly improved infarct size, LV ejection fraction, and adverse LV remodeling, changes associated with decreased neutrophils in the heart. In an ischemic cardiomyopathy model, mice 4 weeks post–myocardial infarction were randomized to tail-vein injection of 2×10 6 MSCs, with injection repeated at week 3 (n=16) versus PBS control (n=16). MSCs significantly increased LV ejection fraction and decreased LV end-systolic volume. Conclusions:: Intravenously administered MSCs for acute myocardial infarction attenuate the progressive deterioration in LV function and adverse remodeling in mice with large infarcts, and in ischemic cardiomyopathy, they improve LV function, effects apparently modulated in part by systemic anti-inflammatory activities.


  • Top Cited Papers

    Inflammation as a Driver of Adverse Left Ventricular Remodeling After Acute Myocardial Infarction

    by Peter C. Westman, Michael J. Lipinski, Dror Luger, Ron Waksman, Robert O. Bonow, Edwin Wu, Stephen E. Epstein


  • Percutaneous Coronary Intervention Versus Medical Therapy in Stable Coronary Artery Disease

    by Stephen E. Epstein, Ron Waksman, Augusto D. Pichard, Kenneth M. Kent, Julio A. Panza


  • Effects of Aging on the Collateral Circulation, and Therapeutic Implications

    by Stephen E. Epstein, Roberta M. Lassance-Soares, James E. Faber, Mary Susan Burnett


  • The Role of Infection in Atherosclerosis and in Plaque Stability

    by Stephen E. Epstein, Jianhui Zhu, Amir H. Najafi, Mary Susan Burnett

  • Aging Causes Collateral Rarefaction and Increased Severity of Ischemic Injury in Multiple Tissues

    by James E. Faber, Hua Zhang, Roberta M. Lassance-Soares, Pranay Prabhakar, Amir H. Najafi, Mary Susan Burnett, Stephen E. Epstein

    Objective—: Aging is a major risk factor for increased ischemic tissue injury. Whether collateral rarefaction and impaired remodeling contribute to this is unknown. We quantified the number and diameter of native collaterals and their remodeling in 3-, 16-, 24-, and 31-month-old mice. Methods and Results—: Aging caused an “age-dose-dependent” greater drop in perfusion immediately after femoral artery ligation, followed by a diminished recovery of flow and increase in tissue injury. These effects were associated with a decline in collateral number, diameter, and remodeling. Angiogenesis was also impaired. Mechanistically, these changes were not accompanied by reduced recruitment of T cells or macrophages to remodeling collaterals. However, endothelial nitric oxide synthase signaling was dysfunctional, as indicated by increased protein nitrosylation and less phosphorylated endothelial nitric oxide synthase and vasodilator-stimulated phosphoprotein in collateral wall cells. The cerebral circulation exhibited a similar age-dose-dependent loss of collateral number and diameter and increased tortuosity, resulting in an increase in collateral resistance and infarct volume (eg, 6- and 3-fold, respectively, in 24-month-old mice) after artery occlusion. This was not associated with rarefaction of similarly sized arterioles. Collateral remodeling was also reduced. Conclusion—: Our findings demonstrate that aging causes rarefaction and insufficiency of the collateral circulation in multiple tissues, resulting in more severe ischemic tissue injury.


    • 1 April 2011
      • Vol. 124  (7) , 1075-81

    Effects of aging on time course of neovascularization-related gene expression following acute hindlimb ischemia in mice.

    by Jin-Song Wang, Xia Liu, Zhen-Yi Xue, Lee Alderman, Justin U Tilan, Remi Adenika, Stephen E Epstein, Mary Susan Burnett

    Molecular analysis of neovascularization related genes by time course in response to ischemia has not been described in the context of aging. We aimed to provide a progressively deeper understanding of how aging compromises neovascularization. Young (3-month) and old (18-month) C57Bl mice were subjected to left hindlimb ischemia. Necrosis score was evaluated in calf muscles. Calf muscles, peripheral blood, bone marrow were harvested at different time points. The expressions of matrix metalloproteiniase-9 (MMP9), endothelial nitric oxide synthase (eNOS), vascular endothelial growth factor (VEGF), stromal derived growth factor-1 (SDF1), hypoxia inducible factor-1α (HIF1α), VEGF receptor-1 (Flt1), VEGF receptor-2 (Flk1), angiopoietin-1 (Ang1), CD133, CD26 were detected by RT-PCR or Western blotting. White blood cells were counted in the peripheral blood. Gene expression data were compared by two-way analysis of variance. MMP9, HIF-1α and SDF-1 were more upregulated during acute ischemia in old vs. young mice, reflecting increased ischemia in aging mice. However VEGF and eNOS exhibited lower expression in old vs. young mice, despite greater ischemia intensity. Ang1 and Flk1 showed similar expression in old vs. young mice. MMP9 peaked earlier in peripheral blood in young vs. old mice. Concurrent decreasing CD26 and increasing CD133 expression in aging bone marrow suggest aging impairs progenitor cell mobilization, Our results indicate that a complex array of defects occur with aging that interfere with optimal neovascularization. These include potential impaired mobilization of progenitor cells to ischemic tissue, decreased levels of eNOS and VEGF and delayed responses to ischemia.


  • The complexity of ABO in coronary heart disease – Authors' reply

    by Muredach P Reilly, Jane F Ferguson, Jing He, Mingyao Li, Stephen E Epstein, Daniel J Rader

  • Open Access

    Pathway-Wide Association Study Implicates Multiple Sterol Transport and Metabolism Genes in HDL Cholesterol Regulation

    by Kai Wang, Andrew C. Edmondson, Mingyao Li, Fan Gao, Atif N. Qasim, Joseph M. Devaney, Mary Susan Burnett, Dawn M. Waterworth, Vincent Mooser, Struan F. A. Grant, et al.

    Pathway-based association methods have been proposed to be an effective approach in identifying disease genes, when single-marker association tests do not have sufficient power. The analysis of quantitative traits may be benefited from these approaches, by sampling from two extreme tails of the distribution. Here we tested a pathway association approach on a small genome-wide association study (GWAS) on 653 subjects with extremely high high-density lipoprotein cholesterol (HDL-C) levels and 784 subjects with low HDL-C levels. We identified 102 genes in the sterol transport and metabolism pathways that collectively associate with HDL-C levels, and replicated these association signals in an independent GWAS. Interestingly, the pathways include 18 genes implicated in previous GWAS on lipid traits, suggesting that genuine HDL-C genes are highly enriched in these pathways. Additionally, multiple biologically relevant loci in the pathways were not detected by previous GWAS, including genes implicated in previous candidate gene association studies (such as LEPR, APOA2, HDLBP, SOAT2), genes that cause Mendelian forms of lipid disorders (such as DHCR24), and genes expressing dyslipidemia phenotypes in knockout mice (such as SOAT1, PON1). Our study suggests that sampling from two extreme tails of a quantitative trait and examining genetic pathways may yield biological insights from smaller samples than are generally required using single-marker analysis in large-scale GWAS. Our results also implicates that functionally related genes work together to regulate complex quantitative traits, and that future large-scale studies may benefit from pathway-association approaches to identify novel pathways regulating HDL-C levels.


  • Insights Into the Role of Infection in Atherogenesis and in Plaque Rupture

    by Stephen E. Epstein, Jianhui Zhu, Amir H. Najafi, Mary S. Burnett